Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
MiR34A, B and C have been implicated in lymphomagenesis, but information on their role in normal CD19+ B-cells (PBL-B) and de novo diffuse large B-cell lymphoma (DLBCL) is limited.
Main Authors: | Asmar, Fazila, Hother, Christoffer, Kulosman, Gorjan, Treppendahl, Marianne Bach, Nielsen, Helene Myrtue, Ralfkiaer, Ulrik, Pedersen, Anja, Møller, Michael Boe, Ralfkiaer, Elisabeth, de Nully Brown, Peter, Grønbæk, Kirsten |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039115/ |
Similar Items
-
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing
by: Kristensen, Lasse Sommer, et al.
Published: (2013) -
Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma
by: Kristensen, Lasse Sommer, et al.
Published: (2014) -
Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL
by: Knudsen, Steen, et al.
Published: (2015) -
TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy
by: Munch-Petersen, Helga D., et al.
Published: (2016) -
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
by: Nordström, Lena, et al.
Published: (2014)